ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

OBI Ondine Biomedical Inc.

9.25
-0.50 (-5.13%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ondine Biomedical Inc. LSE:OBI London Ordinary Share CA68234M2058 COM SHS NPV (CDI)
  Price Change % Change Share Price Shares Traded Last Trade
  -0.50 -5.13% 9.25 39,379 15:09:10
Bid Price Offer Price High Price Low Price Open Price
9.00 9.50 9.75 9.25 9.75
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics CAD 638k CAD -19.37M CAD -0.0996 -0.93 18M
Last Trade Time Trade Type Trade Size Trade Price Currency
15:45:12 O 210 9.50 GBX

Ondine Biomedical (OBI) Latest News (5)

Ondine Biomedical (OBI) Discussions and Chat

Ondine Biomedical Forums and Chat

Date Time Title Posts
28/3/202415:50O B I 506
26/3/202419:35Steriwave is on track to be approved in the US in 2024317
31/8/202311:28Potential8

Add a New Thread

Ondine Biomedical (OBI) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
15:45:139.5021019.95O
15:40:249.00514.59O
15:09:129.372,000187.40O
15:09:109.501009.50O
15:09:109.50151.43O

Ondine Biomedical (OBI) Top Chat Posts

Top Posts
Posted at 28/3/2024 08:20 by Ondine Biomedical Daily Update
Ondine Biomedical Inc. is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker OBI. The last closing price for Ondine Biomedical was 9.75p.
Ondine Biomedical currently has 194,584,524 shares in issue. The market capitalisation of Ondine Biomedical is £17,999,068.
Ondine Biomedical has a price to earnings ratio (PE ratio) of -0.93.
This morning OBI shares opened at 9.75p
Posted at 20/3/2024 08:32 by z1co
In September 2023 the company said review meeting held with the FDA on September 22, 2023 confirmed that the Company has satisfied the FDA's pre-clinical and safety requirements and will be working closely with the FDA on specific details of the Phase 3 protocol. Finalising preparations with HCA Healthcare for Phase 3 clinical trial.

In December 2023 they commented that they are continuing to work closely with HCA - the largest hospital group in the United States - to prepare for the Phase 3 trial in circa 14 HCA hospitals as part of its Ondine's submission to the FDA for approval.

At some point very soon these pivotal US phase 3 clinical trials will get started and when we get confirmation via an rns , expect the shares to rise 50% to 100%.

It's almost a certainty that they will get the FDA approval and that's when the real upward explosion of the share price will take place >>>>>>>>>> 50p to £1.
Posted at 05/3/2024 19:46 by bamboo2
Re, "Gets sold into albeit small volume and it still falls

Why ? Market does not see any meaningful revenues soon"

=====================================

There is effectively no 'market' as such for these shares. It's really hard to find a platform that offer them. I had to go to AJBell to get mine, as Halifax wouldn't sell them. Even on AJB there is often no quote to buy or sell. Further more, it's often impossible to place a buy or sell order.

This share is symbolic of the failure of the UK market to take pre-profit tech shares seriously.

=====================================

Ondine starts first UK health economics study

The York Health Economic Consortium will undertake the first UK health economic analysis of Ondine's Steriwave light-activated antimicrobial to reduce Surgical Site Infections

Ondine Biomedical Inc. (LON:OBI), Mid Yorkshire Teaching NHS Trust, and Health Innovation Yorkshire and Humber are partnering with the York Health Economics Consortium (YHEC) to evaluate the use of Ondine's light-activated antimicrobial, Steriwave®, to reduce the incidence of surgical site infections (SSIs).

SSIs are one of the most common healthcare-associated infections (HAIs) and affect one in every 20 patients who undergo a surgical procedure in the NHS. SSIs can cost up to £100,000 per patient, and the overall cost of HAIs to NHS England is over £2 billion a year. These costs are expected to rise as growing rates of antimicrobial resistance (AMR) make the current standard of care - the antibiotic mupirocin - less effective.



Steriwave uses a proprietary photosensitizer, which is activated by a specific wavelength of red light, to eliminate infection-causing pathogens in the nose. The nose is a reservoir for pathogens like Staphylococcus aureus and MRSA which are known to cause SSIs. Steriwave eliminates these pathogens, including superbugs, in a painless five-minute treatment and prevents them from spreading and causing infections. Importantly, unlike today's antibiotics, the use of Steriwave does not trigger antimicrobial resistance.


The health economic analysis is being undertaken by YHEC, an internationally renowned provider of health economics evaluations, and will supplement the ongoing Steriwave pilot at Mid Yorkshire Teaching NHS Trust, which involves 500 elective hip and knee surgery patients over a period of six months. The findings will be used to support adoption of Steriwave across the NHS.

Dr Stuart Bond, Consultant Antimicrobial Pharmacist and Director of Innovation at Mid Yorkshire Teaching NHS Trust, commented: "We are very pleased to be partnering with Ondine and the YHEC on this economic analysis to support the promising results of the Steriwave pilot we have seen so far. The data from the health economic analysis will support the results of our pilot, and we hope to be able to share these later this year."

Helen Hoyland, Head of Health Innovation Yorkshire & Humber's Office of Life Sciences portfolio, said: "Health Innovation Yorkshire and Humber (formerly the Academic Health Science Network for the region) is pleased to be supporting this evaluation. We are commissioned by the Office of Life Sciences to support real-world evidence generation. We will work with the innovators and the Trust to publish the evaluation data, and then subsequently look to support further opportunities for the spread and adoption of Steriwave, working alongside the West Yorkshire Innovation Hub".

Steriwave is also being used in major hospitals across Canada, including Vancouver General Hospital (VGH), The Ottawa Hospital (TOH), and the Mazankowski Alberta Heart Institute. Research recently published by VGH in the Canadian Journal of Surgery showed that the use of Steriwave in patients undergoing spine surgery resulted in a 66.5% reduction in post-surgical infection rates and $2.5 million in annual savings.[i] No serious adverse events have ever been reported from Steriwave treatment.
Posted at 05/3/2024 18:22 by z1co
Finally some news

Ondine starts first UK health economics study

The York Health Economic Consortium will undertake the first UK health economic analysis of Ondine's Steriwave light-activated antimicrobial to reduce Surgical Site Infections

Ondine Biomedical Inc. (LON:OBI), Mid Yorkshire Teaching NHS Trust, and Health Innovation Yorkshire and Humber are partnering with the York Health Economics Consortium (YHEC) to evaluate the use of Ondine's light-activated antimicrobial, Steriwave®, to reduce the incidence of surgical site infections (SSIs).

SSIs are one of the most common healthcare-associated infections (HAIs) and affect one in every 20 patients who undergo a surgical procedure in the NHS. SSIs can cost up to £100,000 per patient, and the overall cost of HAIs to NHS England is over £2 billion a year. These costs are expected to rise as growing rates of antimicrobial resistance (AMR) make the current standard of care - the antibiotic mupirocin - less effective.



Steriwave uses a proprietary photosensitizer, which is activated by a specific wavelength of red light, to eliminate infection-causing pathogens in the nose. The nose is a reservoir for pathogens like Staphylococcus aureus and MRSA which are known to cause SSIs. Steriwave eliminates these pathogens, including superbugs, in a painless five-minute treatment and prevents them from spreading and causing infections. Importantly, unlike today's antibiotics, the use of Steriwave does not trigger antimicrobial resistance.


The health economic analysis is being undertaken by YHEC, an internationally renowned provider of health economics evaluations, and will supplement the ongoing Steriwave pilot at Mid Yorkshire Teaching NHS Trust, which involves 500 elective hip and knee surgery patients over a period of six months. The findings will be used to support adoption of Steriwave across the NHS.

Dr Stuart Bond, Consultant Antimicrobial Pharmacist and Director of Innovation at Mid Yorkshire Teaching NHS Trust, commented: "We are very pleased to be partnering with Ondine and the YHEC on this economic analysis to support the promising results of the Steriwave pilot we have seen so far. The data from the health economic analysis will support the results of our pilot, and we hope to be able to share these later this year."

Helen Hoyland, Head of Health Innovation Yorkshire & Humber's Office of Life Sciences portfolio, said: "Health Innovation Yorkshire and Humber (formerly the Academic Health Science Network for the region) is pleased to be supporting this evaluation. We are commissioned by the Office of Life Sciences to support real-world evidence generation. We will work with the innovators and the Trust to publish the evaluation data, and then subsequently look to support further opportunities for the spread and adoption of Steriwave, working alongside the West Yorkshire Innovation Hub".

Steriwave is also being used in major hospitals across Canada, including Vancouver General Hospital (VGH), The Ottawa Hospital (TOH), and the Mazankowski Alberta Heart Institute. Research recently published by VGH in the Canadian Journal of Surgery showed that the use of Steriwave in patients undergoing spine surgery resulted in a 66.5% reduction in post-surgical infection rates and $2.5 million in annual savings.[i] No serious adverse events have ever been reported from Steriwave treatment.
Posted at 26/1/2024 07:28 by z1co
ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

Ondine unveils new research at SPIE Photonics West

Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) will present new research at the SPIE Photonics West conference in San Francisco, California. The presentation will provide details of an exploratory study showing that photodisinfection significantly reduces pathogens in the nose - a reservoir for bacteria - yet does not produce long-term adverse effects on the nasal microbiome.1 Organised by SPIE, the international society for optics and photonics, SPIE Photonics West is the largest annual event for optic and photonic technologies and one of the largest scientific conferences in the world.

These results demonstrate that Steriwave is an effective, potent, short-acting, and non-selective method of nasal decolonization, while permitting rapid recovery of the native microbiome at one week after treatment. The study involved analyzing nasal swabs from 35 healthy volunteers after being treated with Ondine's Steriwave® Nasal Photodisinfection System.

The oral presentation will be delivered by Ondine's Director of Research and Development, Dr Caetano Sabino, at 9am on Tuesday, 30 January 2024, as part of the "Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases" session.

The "Microbiome Analysis of Photodynamic Nasal Decolonization" abstract can be accessed here.

_________

1 The nasal microbiome consists of a complex community of microorganisms - fungi, parasites, viruses, and bacteria - that can act in a symbiotic relationship in the nasal cavity.
Posted at 11/1/2024 15:00 by z1co
Since you like replying when you're called a troll.

A special educational post for you troll.

I've bought these shares for the 12 to 18 months time frame just like i bought CSFS over a year ago when they were around 6p to 7p.

Take a look at CSFS price is up 5 fold.

OBI share price will no doubt rise over the short , medium and long term.

For your education you just keep watching and posting on the forum.

nb I have available funds to buy more if i decide to.
Posted at 11/12/2023 18:35 by bamboo2
11 December 2023

Ondine Biomedical Inc.

("OBI", "Ondine", or the "Company")

Result of Fundraising

Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company, announces the close of the Broker Option, and the successful completion of the Fundraising (comprising the Placing, Subscription and Broker Option), raising c.GBP2.85 million ( C$4.91 million ) in total.

Further to the announcement on 5 December 2023 regarding the Placing and the Subscription, a further 1,136,110 new shares (the "New Shares") will be issued pursuant to the Broker Option. The Fundraising was completed at an issue price of 9 pence (the "Issue Price") which represents a premium of approximately 9 per cent. to the closing mid-price of the Common Shares on 29 November 2023 (being the day prior to the launch of the Fundraising).

After the deduction of associated fees and expenses, the net proceeds of GBP2.45 million (C$4.22 million) receivable by the Company from the Fundraising (comprising the Placing, Subscription and Broker Option) will be used principally to support the Company's ongoing commercialisation efforts focused in Canada, the UK, Spain and Mexico and to provide general working capital. The net proceeds from the Fundraising will provide further cash runway until at least mid Q2 2024. The Company continues to evaluate funding opportunities for its Phase 3 study in the US, subject to the finalisation of the trial design with the FDA, and for further commercial development internationally.

Admission, Settlement and Dealings

The 30,555,553 Common Shares issued pursuant to the Placing and Subscription were admitted to trading on AIM on 8 December 2023. The New Shares to be issued pursuant to the Broker Option will be admitted to trading on AIM on or around 15 December 2023 ("Admission").

The New Shares, when issued, will be fully paid and will rank pari passu in all respects with the Existing Common Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue.

Total Voting Rights

As at the date of this announcement and taking into account the Placing Shares and the Subscription Shares, the issued share capital and total voting rights in the Company is 225, 617,679. This figure may be used as the denominator for the calculations by which shareholders will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Following admission of the New Shares issued pursuant to the Broker Option, the Company's issued and fully paid share capital will consist of 226,753,789 Common Shares, each carrying one voting right per share. The Company does not hold any Common Shares in treasury. Therefore, from 15 December 2023, the total number of Common Shares and voting rights in the Company is expected to be 226,753,789.
Posted at 05/12/2023 11:52 by bamboo2
5 December 2023

Ondine Biomedical Inc.

("OBI", "Ondine", or the "Company")

Result of Placing and Subscription

Broker Option to raise up to GBP1.25 million

Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company, is pleased to confirm, further to the announcement made on 30 November 2023, (the "Launch Announcement"), the successful completion of the Placing and Subscription at the Issue Price of 9 pence per New Common Share. The Issue Price represents a premium of approximately 9 per cent. to the closing mid-price of the Common Shares on 29 November 2023.

The total gross proceeds of the Placing and the Subscription to date stand at approximately GBP2.75 million (C$4.74 million).

The Placing has conditionally raised aggregate gross proceeds of approximately GBP2.03 million (C$3.50 million) pursuant to the placing of 22,554,435 Placing Shares with new and existing investors. The Subscription has raised further gross proceeds of approximately GBP0.72 million (C$1.24 million) pursuant to subscriptions received for 8,001,118 Subscription Shares, excluding any further subscriptions by employees (the "Employee Subscription").

The 30,555,553 New Common Shares in aggregate to be issued pursuant to the Placing and the Subscription represent approximately 15.7 per cent. of the existing issued share capital of the Company.

All shares issued pursuant to the Placing and Subscription will be issued non pre-emptively under the Company's existing authorities, and are expected to be admitted to trading on AIM on or around 8 December 2023.

Singer Capital Markets Securities Limited ("SCM") and RBC Europe Limited ("RBC") acted as Joint Bookrunners for the Placing. The Placing was conducted following a market sounding by way of an accelerated book build process.

Further to the announcement on 4 December 2023, a Broker Option to raise up to GBP1.25 million (C$2.15 million) will remain open until 4.45pm on 8 December 2023, in order to satisfy potential further demand from institutional investors and other Relevant Persons. If the Broker Option is exercised in whole or in part, further announcements will be made as appropriate. Any further issuance of New Common Shares following any exercise of the Broker Option will be made on a non pre-emptive basis.

Similarly, any further issuance pursuant to the Employee Subscription will be confirmed by way of a further announcement on or before 8 December 2023 and will be made on a non pre-emptive basis. The Employee Subscription will remain open until further notice, but will close in any event by 4.45 p.m. on 8 December 2023.

Related Party Transaction

Certain of the directors of the Company have conditionally subscribed for, in aggregate, 2,187,588 Subscription Shares at the Issue Price, raising gross proceeds of approximately GBP0.20 million (C$0.34 million) for the Company, representing approximately 7.2 per cent of the New Common Shares (assuming a Fundraising of approximately GBP2.75 million (C$4.74 million) from the completed Placing and the Subscription participations confirmed to date).

The number of New Common Shares conditionally subscribed for by each of the Directors, and their resulting shareholdings following the Admission of the Placing Shares and the Subscription Shares subscribed for to date, assuming no new issuance is made arising from the exercise of the Broker Option or any further subscriptions by employees, are set out below:


Director Number of New Total Number % of issued share
Common Shares of New Common capital as enlarged
subscribed for Shares held on by the completed
in the Subscription Admission Placing and Subscription
to date(1)
Carolyn Cross(2) 1,093,770 135,328,279 59.98%
--------------------- ---------------- --------------------------
Nicolas Loebel 218,754 2,852,088 1.26%
--------------------- ---------------- --------------------------
Craig Tooman 173,278 173,278 0.08%
--------------------- ---------------- --------------------------
Jean Duval 207,934 207,934 0.09%
--------------------- ---------------- --------------------------
Junaid Bajwa 190,610 317,735 0.14%
--------------------- ---------------- --------------------------
Michael Farrer 86,642 86,642 0.04%
--------------------- ---------------- --------------------------
Simon Sinclair 216,600 472,927 0.21%
--------------------- ---------------- --------------------------

1 These figures are subject to change in the event of further new issuance under the Employee Subscription or as a result of the exercise of some or all of the Broker Option.

2 Existing beneficial holding includes 108,376109 shares held by Mrs Carolyn Cross, including via holdings in 100% owned companies, and 25,858,400 shares held by Mr Robert Cross, husband of Mrs Carolyn Cross.

The subscriptions by the Participating Directors constitute a related party transaction for the purposes of Rule 13 of the AIM Rules by virtue of such persons being directors of the Company and therefore related parties (the "Transaction"). The director independent of the Participating Directors, being Hon. Jean Charest, considers, having consulted with the Company's nominated adviser, that the terms of the participation by the Participating Directors, are fair and reasonable insofar as the Company's shareholders are concerned.

Admission, Settlement and Dealings

Admission of the Placing Shares and Subscription Shares will take place on or before 8.00 a.m. on 8 December 2023 and dealings on AIM in the Placing Shares and the Subscription Shares (excluding any to be issued from the Employee Subscription) will commence at the same time. Admission is conditional upon, among other things, the Placing Agreement not having been terminated and becoming unconditional in all respects.

The Placing Shares and Subscription Shares when issued, will be fully paid and will rank pari passu in all respects with the Existing Common Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue.

Total Voting Rights

Following admission of the Placing Shares and Subscription Shares (excluding any arising from the Broker Option or Employee Subscription), the Company's issued and fully paid share capital will consist of 225,617,679 Common Shares, all of which carry one voting right per share. The Company does not hold any Common Shares in treasury. Therefore, the total number of Common Shares and voting rights in the Company will be 225,617,679 after the admission of the Placing Shares and the Subscription Shares (excluding any from the Broker Option Employee Subscription)
Posted at 10/11/2023 11:59 by z1co
Yeh iv'e heard that from you before as well for someone to pay advfn £10 just to post on a thread that makes you a proper troll.

Get your monies worth while the share price is low because you'll be long gone when the share price starts to rise strongly.

a troll like you will never change.

I expect the company to announce more hospital take ups as well pilots very soon.Phase 3 trials will also be starting very soon.

Plenty of positive news to look forward to.

Very relaxed holding the shares
Posted at 09/11/2023 20:13 by z1co
Beeks of Arabia

You remind me of another troll that started to deramp CSFS at the beginning of the year when the CSFS share price was around 6.25p.

He was also deramping the same way that you're doing ie share placing etc etc

He eventually run off with his tail firmly stuck between his legs when the share price started to rise and it eventually reached 18p and that's exactly what will happen to you.

These shares are poised to rerate massively near term.

OBI will at least double over the next few months.

Meanwhile CLCO will fall even more over the next few months.
Posted at 18/10/2023 06:50 by bamboo2
Ondine Biomedical Inc. Steriwave shown to reduce resistant bacteria
18/10/2023 7:00am
RNS Non-Regulatory

TIDMOBI

Ondine Biomedical Inc.

18 October 2023

18 October 2023

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Steriwave shown to reduce resistant bacteria by >99.9%

-- New research presented by Ondine shows that Steriwave photodisinfection reduces antibiotic-resistant bacteria by more than 99.9% without generating resistance.

-- The research suggests that photodisinfection is a viable alternative to antibiotics.
Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) is today presenting new research showing that Steriwave (R) photodisinfection reduced antibiotic-resistant bacteria by more than 99.9%. The in vitro study, which is being presented today at the IP2023 Annual conference taking place in Liverpool 17-19 October 2023, indicates that photodisinfection is likely to play an important role in strategies for combatting antimicrobial resistance (AMR).

The controlled study evaluated the efficacy of Ondine's Steriwave (R) photodisinfection against Gram-negative and Gram-positive multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria with novel antibiotic resistance factors. All of the bacterial strains used in the study exhibited resistance against some of the most commonly prescribed antibiotic classes, including penicillin, tetracyclines, quinolones and carbapenems.

The results of the study showed that treatment with photodisinfection resulted in >99.9% reduction of viable bacteria compared to the control, regardless of the antibiotic susceptibility of the bacteria. The authors concluded that photodisinfection is likely an important adjunct to AMR strategies in the future and that further clinical studies are warranted.

Antimicrobial resistance (AMR) remains a major public health concern, causing 33,000 deaths in Europe annually ([1]) which is projected to rise to over 10 million globally by 2050. ([2]) There are widespread multidrug-resistant (MDR) and extensively drug-resistant (XDR) infections across the world which are mainly caused by Gram-negative bacteria including Enterobacteriaceae and P. aeruginosa AMR bacteria ([3]) (, [4]) and Gram-positive bacteria such as Staphylococcus spp. ([5]) Steriwave has been found to be highly effective against all these pathogens.

Photodisinfection uses a photosensitizer and a specific wavelength of light to trigger photochemical reactions that produce reactive oxygen species. These reactive oxygen species are lethal to a broad spectrum of microbes, including bacteria, fungi, and viruses. Importantly, photodisinfection does not induce antimicrobial resistance formation.

Carolyn Cross, CEO of Ondine, commented:

"We continue to demonstrate, both clinically in hospitals across Canada and in the lab, that photodisinfection can provide a real alternative to topical antimicrobials which are no longer effective against an increasing number of pathogens. The evidence continues to show that photodisinfection destroys all types of pathogens including viruses, bacteria and fungi even those in biofilm, and we believe this technology can save millions of lives. The results of this study are particularly welcome as we prepare for our US Phase 3 trial in partnership with HCA Healthcare who are providing invaluable guidance and support."

The poster presentation, "Antimicrobial Photodynamic Therapy Against Extensively Drug-Resistant (XDR) Gram Negative Isolates With Novel Antibiotic Resistance Factors", is being presented at IP2023 between 1:10pm and 2:40pm (BST) on 18 October 2023.
Ondine Biomedical share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock